Sponsored Links
| Actelion's Novel CRTH2 Antagonist Meets Primary Endpoint In Phase II Study In Patients With Seasonal Allergic Rhinitis |
 |
 |
 |
| Medical News - Allergy | |
|
Actelion Ltd (SIX: ATLN) today announced that a Phase II study with its novel orally-active CRTH2 antagonist in seasonal allergic rhinitis has met its primary endpoint with statistical significance (pThe study assessed the efficacy and tolerability of various doses of this novel CRTH2 antagonist in adult patients with seasonal allergic rhinitis ("hay fever") due to mountain cedar pollen... Read more: Allergy News From Medical News Today
|